Novaliq Gmbh

Molecular Health Gmbh

The University of Texas System

Hartmut Voss

Frank Löscher

Dieter Scherer

Ralf Grillenberger

Markus Beier

Bernhard Günther

Anil K Sood

Sonja Krösser

David B Jackson

Stephan Brock

Thomas Schlüter

Kirsten Eickhoff

Alice Meides

Martin Stein

Jörg Haisser

Daniela Willen

Christopher G Danes

Frank Loscher

Sonja Krosser

Jorg Haisser

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

Ophthalmic composition for treatment of dry eye disease

The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.

Semifluorinated compounds and their compositions

The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.

Opthalmic compositions comprising F6H8

The present invention is directed to certain semifluorinated compounds and to compositions comprising such compounds. The invention further provides the use of the compounds and of the compositions as medicaments for topical administration to the eye.

Semifluorinated compounds

There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex, termed NEPOR. Presence of NEPOR components on a tumor allows EPO to impinge on the survival of associated cells thereby enhancing tumor progression and negatively effecting patient survival. Presence of NEPOR represents a prognostic biomarker for poorer patient outcome. Thus, methods are provided for stratifying patients having a tumor as suitable (i.e. NEPOR not present) or non-suitable (i.e., NEPOR present) for EPO treatment, comprising: (a) isolating a tissue sample from an individual who is receiving or is a candidate for receiving erythropoietin, (b) determining the level of expression of the NEPOR gene(s) (mRNA) and/or the presence of the NEPOR gene product (protein) from the isolated tissue, and (c) correlating the presence of an NEPOR gene expression product or the presence of NEPOR protein to a physiological response to the treatment with erythropoietin. Furthermore, by disclosing the molecular compositions of NEPOR species, there are disclosed methods for rationally identifying/designing NEPOR modulating therapeutics. Methods also are provided for treating neurological insults such as stroke (via enhancement of NEPOR activity) and cancer (via down-regulation of cyto-protective signaling from NEPOR).

Tissue protective erythropoietin receptor (NEPOR) and methods of use

Growing community of inventors

Schriesheim, Germany

Hartmut Voss